Beta Bionics Q3 2026 net loss widens 71% year over year to $24.35 million; Q3 2026 net sales rise 30% to $35.51 million year over year

Bitget2026/10/27 20:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Beta Bionics’ third-quarter 2026 net loss widened 71% year over year to $24.35 million.
Net sales rose 30% year over year to $35.5 million, while PBP channel net sales more than doubled to $13.6 million.
FDA-cleared Mint is expected to launch commercially across the U.S. in the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610271602PRIMZONEFULLFEED9853632) on October 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Beta Bionics Q3 2026 net loss widens 71% year over year to $24.35 million; Q3 2026 net sales rise 30% to $35.51 million year over year

You may also like

Crypto prices